ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital of Xiamen University
Eli Lilly and Company
Children's Hospital of Philadelphia
The New York Proton Center
Medical University of South Carolina
University of Arizona
Tempus AI
Turning Point Therapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Grupo Espanol de Tumores Neuroendocrinos
Pfizer
Icahn School of Medicine at Mount Sinai
Pfizer
Erasca, Inc.
Taichung Veterans General Hospital
GlaxoSmithKline
Coherus Oncology, Inc.
Dragonfly Therapeutics
Ensem Therapeutics
Centre Oscar Lambret
Merck Sharp & Dohme LLC
IRCCS Azienda Ospedaliero-Universitaria di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna
M.D. Anderson Cancer Center
UMC Utrecht
Hoffmann-La Roche
Università Cattolica di Milano
Eli Lilly and Company
ViroMissile, Inc.
Luzerner Kantonsspital
Vanderbilt-Ingram Cancer Center
Hospices Civils de Lyon
Cancer Research UK
Sichuan Enray Pharmaceutical Sciences Company
Pfizer
Duke University
AstraZeneca
UNC Lineberger Comprehensive Cancer Center
Tizona Therapeutics, Inc
Dana-Farber Cancer Institute
University of California, San Diego
Wake Forest University Health Sciences
Hospices Civils de Lyon
Adaptimmune
University of California, San Diego
Grey Wolf Therapeutics
Manchester University NHS Foundation Trust
Georgetown University
University of California, Davis
Onchilles Pharma Inc